Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biomx Ltd (PHGE)

Biomx Ltd (PHGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 65,876
  • Shares Outstanding, K 69,806
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,170 K
  • EBIT $ -30 M
  • EBITDA $ -28 M
  • 60-Month Beta 1.29
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.90
  • Most Recent Earnings $0.70 on 08/14/24
  • Next Earnings Date 11/12/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.60
  • Number of Estimates 1
  • High Estimate -0.60
  • Low Estimate -0.60
  • Prior Year -1.30
  • Growth Rate Est. (year over year) +53.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8820 +7.00%
on 10/03/24
1.1500 -17.94%
on 09/25/24
-0.0823 (-8.02%)
since 09/18/24
3-Month
0.8820 +7.00%
on 10/03/24
3.4800 -72.88%
on 07/19/24
-2.2563 (-70.51%)
since 07/18/24
52-Week
0.8820 +7.00%
on 10/03/24
8.5500 -88.96%
on 03/06/24
-2.2813 (-70.74%)
since 10/18/23

Most Recent Stories

More News
BiomX Stock Gains From Favorable Study Data Presentation on BX004

BiomX Inc. PHGE recently announced the presentation of data from its Phase 1b/2a study for BX004 — a fixed multi-phage cocktail. BX004 is used for treating cystic fibrosis (CF) patients with chronic...

AXGN : 13.16 (-0.60%)
PHGE : 0.9437 (-0.65%)
TMDX : 126.60 (-0.43%)
KIDS : 27.56 (+2.61%)
BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria,...

PHGE : 0.9437 (-0.65%)
BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria,...

PHGE : 0.9437 (-0.65%)
BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria,...

PHGE : 0.9437 (-0.65%)
BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease

BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the...

PHGE : 0.9437 (-0.65%)
BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria,...

PHGE : 0.9437 (-0.65%)
Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers

BiomX Inc. (NYSE American: PHGE) (“BiomX” or “Company”) announces a new collaboration with Boehringer Ingelheim to identify biomarkers for inflammatory bowel disease (“IBD”). BiomX is a clinical-stage...

PHGE : 0.9437 (-0.65%)
BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria,...

PHGE : 0.9437 (-0.65%)
BiomX Announces Corporate Restructuring

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria,...

PHGE : 0.9437 (-0.65%)
BiomX Announces Publication in the Journal, Bioinformatics

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria,...

PHGE : 0.9437 (-0.65%)

Business Summary

BiomX Ltd is a clinical stage microbiome company. It engages in developing both natural and engineered phage cocktails designed to target and destroy bacteria which affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as IBD, PSC and cancer. BiomX Ltd, formerly known as...

See More

Key Turning Points

3rd Resistance Point 1.0408
2nd Resistance Point 1.0199
1st Resistance Point 0.9818
Last Price 0.9437
1st Support Level 0.9228
2nd Support Level 0.9019
3rd Support Level 0.8638

See More

52-Week High 8.5500
Fibonacci 61.8% 5.6208
Fibonacci 50% 4.7160
Fibonacci 38.2% 3.8112
Last Price 0.9437
52-Week Low 0.8820

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar